The city of Lady Lake, Florida, currently has 9 active clinical trials seeking participants for Alzheimer's Disease research studies.
A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)
NCT06721156
Recruiting
Researchers want to learn if giving MK-1167 (the study medicine) along with acetylcholinesterase inhibitor (AChEI) therapy can improve symptoms of Alzheimer's disease dementia (AD dementia), such as memory and mental activity. AD dementia is the most common type of dementia. AChEI therapy is the standard treatment for AD dementia. The goals of this study are to learn: * If at least one dose level (amount) of MK-1167 works to improve a person's memory and thinking compared to a placebo * About... Read More
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
05/29/2025
Locations: K2 Medical Research THE VILLAGES ( Site 0166), Lady Lake, Florida
Conditions: Alzheimer Disease, Dementia
Register for Updates
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787
Recruiting
The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
05/28/2025
Locations: K2 Medical Research - Lady Lake, Lady Lake, Florida
Conditions: Alzheimer Disease
Register for Updates
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
NCT05026866
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD). Approximately 800 additional participants will be enrolled in a 12-month addendum to assess safety of a different titration regimen.
Gender:
ALL
Ages:
Between 65 years and 80 years
Trial Updated:
05/22/2025
Locations: Care Access - Guava Street, Lady Lake, Florida
Conditions: Alzheimer Disease
Register for Updates
Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease
NCT06268886
Recruiting
The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's Disease.
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
05/22/2025
Locations: Charter Research - Lady Lake, Lady Lake, Florida
Conditions: Alzheimer Disease, Early Onset
Register for Updates
A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease
NCT06544616
Recruiting
The purpose of this study is to assess the effect of JNJ-64042056 on cognitive decline, as measured by Preclinical Alzheimer's disease Cognitive Composite 5 (PACC-5) compared with placebo.
Gender:
ALL
Ages:
Between 55 years and 75 years
Trial Updated:
05/22/2025
Locations: K2 Medical Research, Lady Lake, Florida
Conditions: Preclinical Alzheimer's Disease
Register for Updates
A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
NCT06709014
Recruiting
The goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn about the safety of buntanetap/Posiphen. The main questions it aims to answer are: * Does buntanetap/Posiphen improve cognition as measured by ADAS-Cog13? * Does buntanetap/Posiphen improve function as measured by ADCS-iADL? * What medical issues do participants have, if any, when taking buntanetap/Posiphen? Researchers will compare buntanetap/Pos... Read More
Gender:
ALL
Ages:
Between 55 years and 85 years
Trial Updated:
05/19/2025
Locations: K2 Medical Research, Lady Lake, Florida
Conditions: Early Alzheimers Disease
Register for Updates
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
NCT06653153
Recruiting
The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo. Participation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participat... Read More
Gender:
ALL
Ages:
Between 55 years and 80 years
Trial Updated:
04/16/2025
Locations: K2 MEDICAL Research THE VILLAGES, Lady Lake, Florida
Conditions: Alzheimer's Disease
Register for Updates
A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease
NCT06602258
Recruiting
The primary objective of the study is to determine the dose response of E2814, when concurrently administered with lecanemab, on the change from baseline at 18 months in cerebrospinal fluid (CSF) microtubule-binding region (MTBR)-tau-243 in participants with early Alzheimer's disease (AD).
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
03/31/2025
Locations: Charter Research, Lady Lake, Florida
Conditions: Alzheimer's Disease
Register for Updates
[18F]PI-2620 Phase 3 Histopathological Study
NCT05641688
Recruiting
This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with \[18F\]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and controls during lifetime when compared to histopathology obtained after death and completion of brain autopsy.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
02/21/2025
Locations: K2 Medical Research, Lady Lake, Florida
Conditions: Alzheimer Disease
Register for Updates